Evidence map›Paper›PMID 41847154›Full record

ArticleJTO clinical and research reports2026

Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in

Shinkichi Takamori, Toshio Shimokawa, Atsushi Osoegawa, Miyuki Abe, Yohei Takumi, Shunichi Sugawara, Seiji Niho, Yasushi Goto, Hiroaki Okamoto, Katsuyuki Hotta and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shinkichi TakamoriDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Atsushi OsoegawaDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Miyuki AbeDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Yohei TakumiDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
Seiji NihoDepartment of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroaki OkamotoDepartment of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Katsuyuki HottaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Yuichi OzawaDepartment of Respiratory Medicine, Hamamatsu Medical Center, Shizuoka, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Hokkaido, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, Wakayama, Japan.
Tetsuya MitsudomiIzumi City General Hospital, Osaka, Japan.
Masafumi YamaguchiDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Concurrent chemoradiotherapy (cCRT) is the standard of care for unresectable stage III NSCLC, but whether Methods: Data from three randomized phase II trials in the Japan Lung Cancer Society database (n = 274; 116 Results: Patients with Conclusion: Patients with

Indexed as

ChemoradiotherapyEGFRLocally advancedLung cancerPrognosis

Identifiers

PMID41847154
PMCPMC12989836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.